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Large randomized controlled trials (RCTs) in preterm infants offer unique opportunities 
for mechanistic evaluation of the risk factors leading to serious diseases, as well as 
the actions of interventions designed to prevent them. Necrotizing enterocolitis (NEC) 
a serious inflammatory gut condition and late-onset sepsis (LOS) are common feeding 
and nutrition-related problems that may cause death or serious long-term morbidity and 
are key outcomes in two current UK National Institutes for Health Research (NIHR) trials. 
Speed of increasing milk feeds trial (SIFT) randomized preterm infants to different rates 
of increases in milk feeds with a primary outcome of survival without disability at 2 years 
corrected age. Enteral lactoferrin in neonates (ELFIN) randomizes infants to supplemen-
tal enteral lactoferrin or placebo with a primary outcome of LOS. This is a protocol for the 
mechanisms affecting the gut of preterm infants in enteral feeding trials (MAGPIE) study 
and is funded by the UK NIHR Efficacy and Mechanistic Evaluation programme. MAGPIE 
will recruit ~480 preterm infants who were enrolled in SIFT or ELFIN. Participation in 
MAGPIE does not change the main trial protocols and uses non-invasive sampling of 
stool and urine, along with any residual resected gut tissue if infants required surgery. 
Trial interventions may involve effects on gut microbes, metabolites (e.g., short-chain 
fatty acids), and aspects of host immune function. Current hypotheses suggest that NEC 
and/or LOS are due to a dysregulated immune system in the context of gut dysbiosis, 
but mechanisms have not been systematically studied within large RCTs. Microbiomic 
Abbreviations: ELFIN, enteral lactoferrin in neonates trial; GCMS, gas chromatography mass spectrometry; HMOs, human 
milk oligosaccharides; iFABP, intestinal fatty acid-binding protein; LCMS, liquid chromatography mass spectrometry; LOS, 
late-onset sepsis; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; NIHR, National Institutes for Health 
Research; PN, parenteral nutrition; RCT, randomized controlled trial; SCFA, short-chain fatty acids; SEM, structural equation 
modeling; SIFT, speed of increasing milk feeds trial; TLf, talactoferrin (recombinant); VOC, volatile organic compound.
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analysis will use next-generation sequencing, and metabolites will be assessed by mass 
spectrometry to detect volatile organic and other compounds produced by microbes 
or the host. We will explore differences between disease cases and controls, as well 
as exploring the actions of trial interventions. Impacts of this research are multiple: 
translation of knowledge of mechanisms promoting gut health may explain outcomes 
or suggest alternate strategies to improve health. Results may identify new non-invasive 
diagnostic or monitoring techniques, preventative or treatment strategies for NEC or 
LOS, or provide data useful for risk stratification in future studies. Mechanistic evaluation 
might be especially informative where there are not clear effects on the primary outcome 
(ISRCTN 12554594).
Keywords: lactoferrin, preterm infant, gut microbiota, metabolome, nutrition, late-onset sepsis, necrotizing 
enterocolitis, mechanistic evaluation
of preterm infants in enteral feeding trails (MAGPIE) study. This 
will examine patterns of gut microbiota and metabolites and will 
be conducted in a subset of infants recruited to the main trials. 
Prospective recruitment to MAGPIE will only be possible for 
infants in the ELFIN study, although research ethics permissions 
exist to analyze samples from around 100 babies in the SIFT study. 
Participation does not affect the main trial protocols or conduct 
and will use safe and non-invasive collection of specimens (urine 
and stool) from ~480 infants from 10 sites. In addition, in those 
infants who undergo surgery, the MAGPIE study will aim to 
retrieve gut tissue from pathology archives after all necessary 
routine clinical tests are completed.
scienTiFic BacKgrOUnD
Prematurity is a major cause of mortality and serious long-term 
morbidity with an enormous burden on health care and educa-
tional systems with total costs to the public sector of approximately 
£UK 3 billion per year in the UK (1). NEC, a serious inflamma-
tory bowel disease, and LOS are responsible for more deaths after 
the first week of life in extremely preterm infants than any other 
single pathology (2). NEC is associated with significant mortality 
(<20–40%) and affects <10% of infants born <32 weeks gestation 
(3–5) and occurs in first few weeks (6). In the UK, there are at 
least 6,000–8,000 births per year <32 weeks (7). LOS will affect 
<20–30% of these infants, of whom 1 in 10 may die (8). National 
data on cause of death in preterm infants are not routinely col-
lected, but extrapolating data from one health region (2) suggests 
there are at least 250 deaths from NEC and LOS alone per year 
in England, although the true figure may be higher because 
postmortems are not always performed and clinical coding can 
be inaccurate. This number of deaths is similar to that for all 
childhood cancers (9), but unlike childhood cancer there is very 
little mechanistic work in preterm infants despite the worldwide 
rate of preterm births continuing to increase (10). NEC and 
LOS are both associated with significant morbidity in survivors 
including worse cognitive outcome and a twofold increase in 
the risk of cerebral palsy, and very high health-care costs: costs 
of surgery for NEC and prolonged intensive care are in excess 
of £UK 100,000 per case (5). In the US, it has been estimated that 
total costs related to the treatment of NEC and its consequences 
inTrODUcTiOn
Preterm delivery is associated with an increased risk of mortality 
and serious morbidities. Among these late-onset sepsis (LOS) and 
necrotizing enterocolitis (NEC) are of particular concern. Adverse 
neurodevelopmental outcome is a major cause of long-term mor-
bidity associated with preterm birth and along with other serious 
medical problems represents a major cost to health-care services 
and society. The UK National Institutes for Health Research 
(NIHR) Health Technology Assessment (HTA) programme has 
funded two large randomized controlled trials (RCTs) of nutri-
tion and feeding in preterm infants born <32 weeks gestation: the 
speed of increasing milk feeds trial (SIFT) (ISRCTN 76463425) 
and the enteral lactoferrin in neonates (ELFIN) trial (ISRCTN 
88261002). These trials are the largest interventional trials in 
preterm infants conducted in the UK and Europe with almost 
5,000 proposed recruits from more than 50 neonatal units. In the 
planning stage, it was anticipated that infants might be eligible 
for recruitment to both as the timing of the trials was predicted 
to overlap. There was, therefore, an explicit intention to enable 
and support recruitment to both trials and avoid unnecessary 
duplication of trial processes and procedures.
In the SIFT trial, 2,804 preterm infants in the UK were ran-
domized to one of two different rates of increase in milk feeds: 
increasing by 18 or 30 ml/kg/day.1 Recruitment commenced in 
August 2013 and completed ahead of schedule in June 2015. The 
primary outcome is survival without moderate or severe disability 
at 2 years corrected age, and follow-up and data collection will not 
complete until 2018. The SIFT protocol allowed for publication 
of key outcomes at hospital discharge including LOS and NEC. 
In the ELFIN trial, 2,200 UK infants are being randomized to 
either receive supplemental enteral bovine lactoferrin or placebo 
(sucrose).2 ELFIN is anticipated to complete toward the end 
of 2017. Both SIFT and ELFIN are pragmatic trials with key 
neonatal morbidities as primary outcomes, but neither included 
mechanistic evaluation.
This publication describes the protocol for a mechanistic 
evaluative study of both trials—the mechanisms affecting the gut 
1 www.npeu.ox.ac.uk/sift.
2 www.npeu.ox.ac.uk/elfin.
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may be in excess of $US 5 billion per year (5). In addition, the 
long-term costs to society, the individual, and their families due 
to lifelong physical and mental impairment are substantial.
The SIFT and ELFIN trials do not include evaluation of dis-
ease pathophysiology. The practicalities of conducting trials in 
multiple sites over prolonged time periods means a pragmatic 
balance has to be reached between the detail and complexity of 
data collection. In SIFT, there were 56 recruiting neonatal units 
(primarily neonatal intensive care units, NICUs) but at least an 
additional 150 neonatal units required research ethics and gov-
ernance approvals to collect and report trial-related data. Over 
100 neonatal units who looked after SIFT babies will therefore be 
required to report data on the primary outcome of disability-free 
survival at 2  years corrected age. In the ELFIN trial, there are 
35 recruiting sites (primarily NICUs) but data collection from 
an additional ~100 neonatal units is required in order to collect 
data until discharge to home. Collecting even limited biological 
samples from all recruited infants would be extremely challeng-
ing and expensive.
The interventions explored in SIFT and ELFIN both act via 
effects on the gut and are therefore likely to involve interactions 
with gut microbiota (2, 11–14). MAGPIE will use the opportu-
nity provided by two large RCTs to explore some of the putative 
actions of the interventions as well as potentially explore disease 
mechanisms where NEC or LOS occur. MAGPIE will do this by 
sampling stool and urine from the infants and use emerging tech-
nologies including next-generation sequencing of gut bacteria, 
and urine and stool mass spectrometry, as windows into host and 
bacterial metabolism, respectively. The aim is to understand some 
of the mechanisms of actions of the interventions and diseases 
and provide new data in the areas of diagnosis, monitoring, and 
therapeutics.
Overview of the siFT and elFin Trials
Speed of increasing milk feeds trial and ELFIN trials are funded 
by the HTA and managed by the National Perinatal Epidemiology 
Unit Clinical Trials Unit, Oxford, UK.3 Both trials recruit very 
preterm infants (<32 weeks gestation) in the first few days after 
birth while receiving care on a neonatal unit. The trial interven-
tions complete prior to hospital discharge, although follow-up for 
SIFT continues until 2 years corrected age. SIFT recruited 2,804 
infants and is powered to detect a clinically important difference 
in disability-free survival at 2 years, as well as having adequate 
power to detect a difference in the rate of the key short-term 
outcomes NEC and LOS. Infants were enrolled when stable, 
tolerating some milk (but less than 30 ml/kg/day), and when the 
attending clinician was ready to start increasing the amount of 
milk feeds. Infants were randomized to increases in milk feeds 
of either 18 or 30 ml/kg/day. Infants from multiple pregnancies 
(twins, triplets, etc.) were corandomized to the same treatment 
arm. It was anticipated that the speed of milk feed increases 
would result in full feeds (defined as at least 145 ml/kg/day) being 
achieved about 4  days later in the slower arm. This affects the 
duration of central venous access and use of parenteral nutrition, 
although this was not mandated in the SIFT protocol and therefore 
3 https://npeu.ox.ac.uk/trials.
is likely to affect two key risk factors for LOS. The speed of milk 
feed increases may also affect exposure to breast milk in the first 
few days of life, a further risk factor for both LOS and NEC. SIFT 
is a trial of comparative clinical effectiveness and recognizes the 
possibility that there might be competing outcomes, i.e., there 
may be opposing impacts on NEC and LOS between the two trial 
arms (15). Hence, the use of disability-free survival as an outcome 
that takes this possibility into account. In addition, if there are 
no differences in key clinical outcomes (including neurological 
development), then data collected for health economic analyses 
may determine which regime is adopted in clinical practice.
The ELFIN trial is evaluating whether supplemental bovine 
lactoferrin added to milk feeds affects the rate of sepsis and is 
powered to detect a clinically important reduction in the primary 
outcome (LOS) from 18 to 13% and will recruit 2,200 infants. 
Infants are randomized to receive either bovine lactoferrin 
(150 mg/kg/day) or placebo 150 mg/kg/day (sucrose) both added 
to milk feeds. The RCT is blinded using masked pots containing 
the investigational medicinal product (IMP). Unlike SIFT, infants 
from multiple pregnancies are randomized independently. An 
internal pilot phase started in June 2014 in five sites, with recruit-
ment to the main trial commencing in July 2015. The trial is cur-
rently in progress and anticipated to complete recruitment toward 
the end of 2017. Further details of the trial are available (16).
existing Mechanistic evaluation of nec 
and lOs in a Prospective Trial setting
Despite the major contribution of NEC and LOS to neonatal mor-
tality and serious morbidity, there are few large interventional 
studies in preterm neonates exploring biological mechanisms. 
This is partly because of the challenges faced by adequately 
powered interventional studies that typically require sample 
sizes of >1,000 infants to detect realistic effects on NEC or LOS. 
Undertaking large clinical studies with mechanistic evaluation in 
vulnerable preterm neonates presents many complexities practi-
cally, logistically, and ethically. There are particular issues with 
biological sampling, especially of blood from small infants, for 
example, a 500-g infant has only 40 ml of total circulating blood 
(17). NICUs are extremely busy environments and clinical needs 
take precedence over activities that are purely research orientated, 
e.g., collection of stool samples. While NEC and LOS are major 
causes of morbidity, they only affect a minority of infants, with 
an incidence of 5–10 and 20%, respectively, in the highest risk 
infants (<32  weeks): a typical NICU may only admit 100–150 
such infants a year. Thus, collaboration between multiple NICUs 
is essential for performing research with sufficient statistical 
power. Securing ethics and R&D approvals, collecting samples 
and accessing freezers close to NICUs, and storing and transport-
ing biological samples across multiple hospital sites present many 
logistic challenges. In addition, the timing of onset of NEC or LOS 
is highly variable and unpredictable meaning that considerable 
“over-sampling” is required to ensure appropriate informative 
sampling relative to disease onset.
Perhaps because of these challenging reasons, few RCTs 
powered to explore differences in NEC or LOS in preterm infants 
have involved biological sampling on a large scale. The largest 
ever UK probiotic trial PiPS (3) explored whether the probiotic 
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strain was detectable in the stool by qPCR at 2  weeks of age 
and 36 weeks corrected gestational age (while infants were still 
receiving the probiotic) and noted (a) in 11% of probiotic-treated 
infants the administered probiotic strain could not be detected 
in their stools and (b) 49% of those receiving placebo had the 
administered probiotic strain in their stools. Broader impact 
on the microbiome in this trial is awaited. These results differ 
from those in a large Australian probiotic trial in preterm infants 
[ProPrems (18)] where microbiome analysis was undertaken in 
43 unblinded infants and showed (a) 8 who were in the active 
intervention group all carried probiotic strains and (b) only 3 
out of 35 infants who were in the placebo group carried any of 
the probiotic strains in stool (19). Again further microbiomic 
impact of colonization status is awaited. Other trials have used 
standard culture to evaluate presence of probiotic strains in the 
stool of infants in an RCT, demonstrating significant differ-
ences in detection rates above or below 27 weeks gestation and 
significant detection in the “placebo” recipients (20, 21). None of 
these nested studies has to date published further microbiomics, 
metabolomics, or other data.
existing Mechanistic evaluative research 
of Feeding rates and supplemental 
lactoferrin
Recent Cochrane systematic reviews of trials of early enteral 
feeding strategies for preterm infants have explored the role of 
trophic feeds, timing of introduction, and rate of increase in feed 
volume (22, 23), but none of these studies incorporated detailed 
mechanistic evaluation of gut function or microbiota. This might 
be important because alterations of gut microbes appear to be 
one of the key mechanisms involved in NEC or LOS pathogenesis 
(12, 13, 24–28). However, whether abnormal gut microbial 
communities are causative, or whether they simply reflect other 
processes involved in disease initiation is uncertain, and so can 
only be adequately explored in prospective trials. In the absence 
of a consistent causative agent in NEC studies, recent data 
demonstrate a specific microbial signature of high diversity and 
dominance of bifidobacteria that may be protective (28).
Breast milk is a complex biological fluid and differs from artifi-
cial formula milk in many respects. Components that differ include 
protein quality (including human lactoferrin), peptides and free 
amino acids, lipids (including long-chain polyunsaturated fatty 
acids), carbohydrates including human milk oligosaccharides 
(HMOs), cells, cytokines, and growth factors (e.g., insulin-like 
growth factor 1, epidermal growth factor, insulin, etc.). HMOs 
cannot be digested by the host, but rather act as growth substrates 
for specific Bifidobacterium spp. (29, 30). In the context of the 
SIFT trial, delayed initiation or slower increases in milk feeds 
reduce exposure to breast milk, which may affect gut epithelial 
development, function, and the pattern of gut microbiota.
At the time of funding MAGPIE, the only existing published 
RCT in preterm infants (n  =  450) using bovine lactoferrin 
showed reductions in the incidence of LOS for a range of bac-
teria, both Gram-negative and Gram-positive, as well as fungi 
(31). The study did not include any mechanistic evaluation using 
biological samples. Subsequently, other studies have confirmed a 
reduction in LOS (32, 33), and further analyses have suggested 
an effect on NEC (34, 35). Recent reviews have highlighted the 
potential mechanisms of action for lactoferrin (36). Lactoferrin, 
a member of the transferrin family, is a key component of the 
mammalian innate immune response (37). It is the major whey 
protein in human colostrum and is also present in tears and other 
secretions, as well as being released from secondary granules in 
poly-morphonuclear leukocytes (38). Concentrations in human 
colostrum are especially high (39). However, preterm infants 
ingest little milk in the first few days, and this may be further 
inhibited by the delayed lactogenesis frequently seen in women 
who deliver preterm. Lactoferrin intake in preterm infants is 
therefore probably far lower than in healthy term neonates.
Lactoferrin has broad microbiocidal activity by mechanisms 
such as cell membrane disruption, iron sequestration, inhibition 
of microbial adhesion to host cells, and prevention of biofilm for-
mation (16, 31, 40, 41). Development of resistance to lactoferrin 
is unlikely as it would require multiple simultaneous mutations. 
Lactoferrin remains a potent inhibitor of viruses, bacteria, fungi, 
and protozoa after millions of years of mammalian evolution (38). 
Lactoferrin has prebiotic properties, creating an environment in 
the gut that might promote the growth of beneficial bacteria and 
reduce colonization with potentially pathogenic organisms (42). It 
has direct intestinal immunomodulatory and anti-inflammatory 
actions mediated by modulating cytokine expression, mobilizing 
leukocytes into the circulation, and activating T-lymphocytes 
(37). Lactoferrin enhances proliferation and differentiation of 
enterocytes, closure of enteric gap junctions, and suppresses free 
radical activity when iron is added to milk.
Although the structure of lactoferrin is broadly similar across 
mammals (43), bovine lactoferrin differs from human lactoferrin, 
so while there are good theoretical reasons why it might have 
beneficial effects, the precise mechanisms of actions in preterm 
infants may differ or may not be present (40, 44–46). A recombi-
nant form of lactoferrin [talactoferrin (TLf)] was also available in 
the US and has been used within an RCT as prophylaxis against 
infection, showing a reduction in fecal staphylococci load to 
almost undetectable levels in infants receiving TLf, and an asso-
ciated reduction in coagulase-negative staphylococci infections. 
The authors also demonstrated a TLf-modulated reduction in 
fecal Enterobacteriaceae postulating that this may be a possible 
mechanism for a reduction in NEC since proteobacteria have 
been associated with NEC development (47).
recent studies of nec and lOs Using 
Microbiomic and Metabolite Data
Necrotizing enterocolitis and LOS are complex multifactorial 
diseases. In particular, a pathological finding of NEC is likely to 
represent the final common pathway of a wide array of patho-
physiological processes (48–51). Recent studies show that NEC 
and LOS are associated with abnormal gut microbial patterns 
including lack of diversity, presence of “marker” bacteria, and 
alterations in bacterial community structures (24, 28, 52, 53). 
However, a key feature of most recent publications is the lack of a 
specific or consistent gut microbiomic signature between studies. 
Since 2011, when the use of next-generation sequencing came 
to the forefront of microbiome research, specific bacterial taxa 
have been associated with NEC onset, particularly those from 
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the Proteobacteria phylum such as Enterobacter, Escherichia, 
Sphingomonas, and Klebsiella spp., although the studies produce 
different findings and many have limited power due to their 
small size.
However, even large studies exploring NEC produce incon-
sistent findings. In a single NICU in Denmark n = 163 preterm 
infants were studied (21 with NEC) and 482 samples analyzed: 
there were no clear differences between NEC and control infants, 
although Gram-positive bacteria appeared more common in NEC 
cases using culture, a result not confirmed in molecular analyses 
(54). In one of the largest studies to date, Warner et al. recruited 
n =  166 infants (46 with NEC) and analyzed 3,587 stools and 
found increased relative abundance of Gamma-proteobacteria 
and reduced Negativicutes (48). Independent of specific bacteria, 
it has also been shown that the overall load of bacteria (52) or 
the presence of fungi have no clear association with NEC onset 
(24, 52). Thus, while the microbiome is undoubtedly important 
to the pathogenesis of NEC, a specific microbe is unlikely to be 
causative. This is in accordance with a recent microbiome and 
metabolome investigation by Stewart et  al., where instability 
of the microbiome and a lack of bifidobacteria were significant 
risk factors for NEC and for the generation of NEC-associated 
metabolites (28). Indeed, metabolites associated with NEC were 
not correlated to any specific bacteria, but were negatively cor-
related with Bifidobacterium. To this end, several recent papers 
have used multi-omic technologies to go beyond “who is there” 
and determine the microbe–host interaction and overall func-
tional profiles. These studies support the notion that different 
microbiome communities can yield more comparability at the 
protein and metabolite level, demonstrating the promise for mass 
spectrometry-based techniques (55–57).
Methodological Issues Associated with Microbiomic 
and Metabolite Analytical Platforms
In exploratory studies, the use of two independent small molecule 
(metabolite) profiling techniques such as liquid chromatography 
mass spectrometry (LCMS) and gas chromatography mass spec-
trometry (GCMS) may improve the detection of metabolites of 
interest. GCMS will detect volatile organic compounds (VOCs) 
that appear to have important consequences for preterm gut 
development and maturation such as short-chain fatty acids 
(SCFAs), and the GCMS protocol we will employ in MAGPIE 
has been extensively optimized to ensure appropriate capture 
of VOCs. Likewise, it is important to employ an LCMS method 
optimized for the high-throughput processing of preterm sam-
ples (28, 57, 58). While GCMS methods are facilitated by spectral 
reference databases for the identifications of compounds, LCMS 
requires standard compounds to be ran to confirm otherwise 
putative identifications from databases that are typically based 
on mass to charge. While validated tools exist for the identifica-
tion of metabolites in untargeted LCMS experiments such as 
Mummichog (59), where appropriate and available matching 
to standard references to confirm identifications is important. 
In addition, the choices of columns (LC) and fibers (GC) can 
have profound effects on the metabolite profiles and the detected 
compounds, so it is important that the methods used are vali-
dated in these sample types. Recent validation work identifying 
peroxidation metabolites in urine from preterm infants provides 
a good example of this approach (60, 61).
Furthermore, the 16S rRNA gene sequencing has been 
extensively applied by several groups to preterm stool research as 
previously described. While this technique will only allow clas-
sification of bacterial hits to genus level, it has proven to be an 
effective technology for microbial ecology-based research. Tools 
such as Tax4Fun (62) and PICRUSt (63) also exist for predicting 
the bacterial metagenome based on the bacteria identified. While 
this inference is predicted, such tools offer an important means 
of investigating the functional capacity of the microbiome, which 
can be further linked to metabolomic data. Therefore, combining 
these different approaches may allow investigators to discern 
“who is there” and “what they are doing (microbe and host).”
However, all of the above techniques have limitations, and there 
are many other factors that are not explored with these methods, 
including genomic, epigenetic, transcriptomic, proteomic, and 
posttranscriptional modification of proteins. However, there is 
already strong data to show that the approaches we aim to use 
in MAGPIE will provide important data. Differences in the pres-
ence of VOCs have already been linked with the development 
of NEC (64) and may also relate to the emergence of LOS (65, 
66). In addition, organisms causing blood culture-positive sepsis 
in preterm infants were frequently detected within the gut prior 
to LOS onset, and typically as an abundant member of the gut 
microbial community (24).
The MAGPIE aims to explore potential interactions between 
microbes and metabolites critical for development of gut immune 
function expanding work from our group and others (67, 68). 
Additional studies highlight the importance of host–microbe 
interactions by demonstrating the pivotal role of SCFAs and other 
compounds in inducing differentiation of gut regulatory T cells 
(69–71), a pathway of major importance in preterm infant NEC 
and LOS.
The MAGPIE may provide insights into the effects of early gut 
microbe/host interactions in establishing gut health and immune 
function. We will build on our existing work that has optimized 
techniques to understand gut inflammation in the presence of 
suppressed or dysregulated immune systems, e.g., inflammatory 
bowel disease (72). These will utilize specialized immunohisto-
chemical analysis of resected diseased and non-affected tissue and 
use computer-aided learning techniques, digital quantification of 
bright field chromogenic staining to explore implicated causal 
biological pathways, especially if there are differences between 
trial arms in SIFT and ELFIN. We will compare diseased cases 
with controls either recruited to the main trials or from recent 
cohorts in our hospitals and examine cell surface markers and 
cytokines that might link microbial and metabolomic changes, as 
well as exploring the potential for transcriptomic analysis.
aiMs anD OBJecTiVes
The aim of the MAGPIE study is to explore differences in gut 
microbiota and metabolic correlates between trial intervention 
arms (feed rate, lactoferrin) and dynamic changes in the period 
preceding disease onset (NEC or LOS). We aim to determine 
effects in both the stool and urinary metabolome, because these 
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may reflect changes in either bacterial or host metabolism, or 
both. Specifically, we will determine changes in the bacterial 
community and overall metabolome profiles using both LCMS 
and GCMS, and using computational tools will determine corre-
lations between the microbiome such as predicted gene orthologs 
and resulting metabolite compounds. Our specific aims are to test 
the following hypotheses:
 1. Trial interventions will result in detectable differences in 
gut microbiota that will be directly related to metabolic 
function;
 2. Infants who develop NEC or LOS will have differences in gut 
microbiota and metabolic profile in the period preceding 
disease onset compared to control infants;
 3. There will be detectable differences in gut tissue inflammatory 
response between surgically resected gut tissue affected by 
NEC and control tissue.
We will achieve these aims by determining the following 
outcomes:
 1. Gut microbial diversity (e.g., Shannon Diversity Index) and 
differences in the proportions of key bacterial taxa measured 
using 16S next-generation sequencing in stool samples col-
lected after enrollment on days 1–3, 7, 10–14, and 21 (±1) 
days.
 2. The association between gut microbiota and the stool 
metabolome using mixed-effect models, structural equation 
modeling (SEM), and ordination analyses. Stool metabolome 
is measured using GCMS and/or LCMS in samples collected 
on days 1–3, 7, 10–14, and 21 (±1) days.
 3. Pattern of gut microbiota prior to the onset of NEC or LOS 
measured using up to seven daily stool samples in the period 
immediately prior to disease compared to samples from con-
trol cases who do not develop disease.
 4. The gut tissue inflammatory response in surgically resected 
gut tissue affected by NEC and in control tissue (either non-
affected tissue from the same infant or tissue from an infant 
requiring gut resection who does not have disease) will be 
determined by immunohistochemistry. This will be measured 
after trial completion by retrieving samples from hospital 
pathology archives.
Our analytical models will also explore the effects of clinical 
risk factors for NEC and LOS such as gestation and markers 
of illness severity, and the effects of exposure to interventions 
such as breast milk and antibiotics, and consider other key out-
comes such as time to full feeds, age at discharge, and growth, 
e.g., predischarge weight gain.
PrOceDUres—sUMMarY
We will
 1. Recruit at least 480 infants from up to 10 neonatal units in the 
UK enrolling infants to ELFIN.
 2. Identify stored samples from infants recruited to SIFT (one 
site only).
 3. Collect a daily stool and urine sample from MAGPIE infants 
until hospital discharge (average duration 40–50  days) or 
transfer back to local neonatal unit.
 4. Retrieve any residual resected gut tissue of enrolled infants 
who undergo intestinal surgery.
 5. Identify samples which are the most:
 a. informative—based on trial intervention and disease 
presence;
 b. comprehensive—consistency of daily sampling;
 c. representative—balanced for trial intervention and other 
key factors, e.g., gestation, breast milk exposure.
 6. Samples to be analyzed will include
 a. all diseased cases: infants who meet the SIFT and ELFIN 
internationally agreed predefined case definitions of confir-
med NEC or LOS following review at Blinded Endpoint 
Review Committee;
 b. non-disease cases: infants who do not develop NEC or 
LOS, selected using matching algorithms to ensure trial 
intervention and risk factor coverage.
 7. The samples analyzed will focus on the early postnatal period 
when trial intervention differences will be greatest: e.g., day 
0—3, 6–8, 9–11, 13–15, and 20–22 in ~25–50 infants per trial 
intervention arm. While we aim for daily sampling we recog-
nize this will not always be achieved due to the complexity 
of the NICU working environment, combined with the fact 
that many sick infants do not pass a stool every day. We will 
also analyze samples at additional time points as necessary 
to ensure a daily sample is analyzed for up to 7 days before 
diagnosis in all diseased cases and match these to non-disease 
controls.
 8. Analyze samples for
 a. gut microbiota using next-generation sequencing on the 
MiSeq (Illumina) platform to determine gut microbial 
patterns;
 b. stool VOC using “headspace” GCMS;
 c. stool metabolomic profile using LCMS to determine pat-
terns in the metabolome;
 d. urine metabolomic profile using LCMS and assays for inflam-
matory proteins, e.g., intestinal fatty acid-binding protein 
(iFABP) where sufficient samples and informative cases exist.
 9. Determine changes due to trial interventions and changes 
preceding disease onset. We will explore dynamic changes 
in the gut community structure: proportions of key bacterial 
operational taxonomy units, presence of specific pathogenic 
strains, diversity, richness, and stability of communities.
 10. Analyze resected gut tissue using optimized immunohisto-
chemistry to determine gut immune response where NEC 
develops. If sufficient samples exist, explore how trial inter-
ventions (feed rate, lactoferrin) and changes in gut microbiota 
or metabolome may relate to histological findings.
 11. Store residual samples in a Human Tissue Act (UK) and 
research ethics approved Newcastle University Biomedicine 
Biobank (the “Great North Neonatal Biobank”) for use in 
future studies.4 HTA license no. 12534, Ethics approval 15/
NE/0334, IRAS 161883.
4 http://www.ncl.ac.uk/nbb/.
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standard Operating Procedures  
(sOPs)—sample collection, storage,  
and Transport
Samples will be collected, anonymized, and analyzed according 
to established SOPs already developed by members of the project 
team. In brief, stool samples are collected from the nappy/diaper 
using a clean disposable plastic spoon and placed in a glass pot 
with a lid. Samples will be collected at routine clinical nursing 
care times. Urine samples are collected according to standard 
NICU procedure, which typically involves collecting urine passed 
spontaneously onto sterile cotton wool ball, squeezed out using a 
sterile syringe, and aliquoted into two 2 ml cryovials. Samples are 
labeled and placed in a −20°C freezer (generally immediately or 
within an hour of collection) located on the NICU. Samples are 
then transferred frozen in batches from local hospitals to central 
laboratories where they will be stored at −80°C prior to micro-
biomic and metabolomic analyses. Transport of samples will 
take place every 6–8 weeks meaning the duration of local storage 
at −20°C is around 1–8  weeks, on average 3–4  weeks. We will 
record sample storage duration at −20 and −80°C and conduct 
analysis throughout the study period in a chronological fashion 
so that we can adjust, if required, for any confounding introduced 
by varying storage durations.
Short-term storage of stool samples does not significantly 
affect the microbial communities, although measurement of stor-
age time of samples is important to avoid potential bias (73–75). 
We aim to account for the amount of time in storage for DNA 
extractions to minimize bias. To determine any storage effects, 
we will conduct quality control by comparing gold standard 
immediate DNA extracts from <10 samples to the same number 
following storage of stool for 12 and 18–24 months.
Any gut tissue resected during surgery for either NEC or 
other conditions (e.g., spontaneous intestinal perforation) will 
be retrieved from paraffin blocks located in NHS pathology 
archives after all clinical tests have been complete. Samples will be 
transported to the central laboratory for immunohistochemical 
analyses. It is possible that only 10–12 infants undergo surgery 
for NEC (or other conditions) and have residual tissue available. 
We will therefore consider the use of control tissue from other 
preterm infants available locally within one hospital (Newcastle 
Hospitals NHS Foundation Trust) where we have research ethics 
permission to analyze historical samples.
enrollment, consent, and Data collection
Parents can be approached for written informed consent at any 
time after enrollment to ELFIN is complete, but this will usually 
be within the first 3 days, and frequently will occur at the same 
time as consent to ELFIN. Written information will explicitly 
state the intention to share and use data collected for ELFIN. 
Research ethics approval allows the collection of stool and urine 
samples and storage on the NICU prior to signed consent for 
MAGPIE, but any such samples will be destroyed if consent is 
not obtained. We will use data collected for SIFT and ELFIN by 
electronic encrypted data transfer from the clinical trials unit 
(NPEU) and supplement this with additional items for MAGPIE 
that include specific antibiotic type, use of prophylactic antifungal 
and probiotic strain/brand if these are used, and date and time of 
stool and urine collection.
case Definitions of Disease (nec or lOs)
We will use the internationally accepted definitions used by 
SIFT and ELFIN, which are subsequently confirmed at Blinded 
Endpoint Review Committees conducted by at least two senior 
clinician investigators blinded to trial interventions at the NPEU.
Late-Onset Sepsis
Microbiological culture of potentially pathogenic bacteria 
(including coagulase-negative staphylococci species but exclud-
ing probable skin contaminants) or fungi from fluid sampled 
aseptically more than 72 h after birth from blood or CSF, or clini-
cally suspected sepsis (meeting three objective clinical criteria) 
AND intention for treatment for 5 or more days with intravenous 
antibiotics. If the infant died, was discharged, or was transferred 
prior to the completion of 5 days of intravenous antibiotics, this 
condition would still be met if the intention was to treat for 5 or 
more days.
Necrotizing Enterocolitis
Necrotizing enterocolitis may be diagnosed at surgery, at 
postmortem or clinically and radiologically: at least one of the 
following clinical signs present: bilious gastric aspirate or emesis, 
abdominal distension, or occult or gross blood in stool AND 
at least one of the following radiological features: pneumatosis 
intestinalis, hepatobiliary gas, or pneumoperitoneum. Infants 
who satisfy the definition of NEC but at surgery or postmortem 
have a “focal gastrointestinal perforation” will not be coded as 
having NEC.
All diseased cases meeting the predefined case definition of 
NEC or LOS will have samples analyzed (expected total ~70–100 
infants). Samples from up to 200 non-diseased cases will be 
selected to ensure sufficient coverage of intervention arms using 
matching algorithms and coverage of other clinical risk factors 
and outcomes. We will also analyze samples from non-diseased 
cases to determine microbiomic and metabolomic profiles 
between trials arms.
laboratory Procedures—stool and Urine
We will analyze bacterial DNA extracted from stool samples using 
our well-established protocols and 16S ribosomal RNA methods 
that are effective tools to explore the diversity of bacterial com-
munities (24, 76, 77). We will conduct metabolomic profiling 
of stool and urine. Extraction of samples will be optimized for 
detection of SCFAs and samples processed using non-targeted 
and targeted high-resolution LCMS to generate metabolomic 
profiles that may indicate functional changes in the host and the 
gut microbiota. Our targeted approach will investigate known 
gut flora fermented products of complex carbohydrates, includ-
ing SCFAs, acetates, amino acids, and carbohydrate fragments, 
which may be present in stool samples. Analysis of the stool 
metabolome reflects changes in gut microbial activity and may 
impact on host gut function such as changes in permeability. Our 
non-targeted approach will allow us to compare metabolomic 
differences between trial arms in order to define a metabolite 
8Embleton et al. Mechanisms Affecting Gut Preterm Infants
Frontiers in Nutrition | www.frontiersin.org May 2017 | Volume 4 | Article 14
pattern associated with sample groups that can be correlated with 
information on microbial diversity, health, or disease.
We have optimized a LCMS method based on C18 reverse 
phase chromatography coupled to a Q-Exactive high-resolution 
mass spectrometer validated on 100 mg of stool and has demon-
strated the robust and reproducible detection of 103 metabolites 
(28, 58). Identification of significant metabolites will be based on 
data-dependent tandem MS/MS and confirmed using standards. 
Analysis (see Statistical Analysis) will use modeling techniques to 
explore relationships between the microbiome and metabolome, 
and study interventions and disease. Examination of the urinary 
metabolome is more reflective of changes to the overall host 
(infant) metabolic state but may also reflect differences in absorp-
tion of compounds from the gut. Determining the metabolomic 
profiles between and within patients to complement the stool 
microbiome sequencing data will enable exploration of how the 
host, gut microbes, trial interventions, and other clinical factors 
may interact, and any downstream functional effects such as feed 
tolerance or growth. To supplement the metabolomic data, we 
will store samples so future studies can analyze urine and stool 
samples using assays for proteins such as calprotectin and iFABP 
that may provide additional diagnostic or mechanistic informa-
tion (78–81).
Volatile organic compounds from stool samples will be ana-
lyzed by GCMS using well-established protocols for extracting 
and analyzing headspace gases. These methods are based on a 
CARB/PDMS SPME fiber, a Combipal sampler with a Peltier-
cooler, and a Perkin Elmer Clarus 600 Gas Chromatograph with 
Clarus 600T Mass Spectrometer (82). The method is validated on 
as little as 50 mg of sample: sufficient to analyze ~40 compounds, 
which includes 8 different acids, particularly SCFAs, branched 
and linear, alcohols, and esters. Interpretation of fragment pat-
terns will be undertaken against the current mass spectral NIST 
library, followed by manual visual inspection (82).
laboratory Procedures—resected  
gut Tissue
The MAGPIE study provides a unique opportunity to explore 
potential gut actions of feeding rate and lactoferrin in a small num-
ber of cases if NEC occurs. This may include immunomodulatory 
and anti-inflammatory actions mediated by modulating cytokine 
expression, mobilizing leukocytes into the circulation, and 
activating T-lymphocytes. Breast milk and lactoferrin enhance 
proliferation and differentiation of enterocytes and closure of 
enteric gap junctions (36). Tissue-based analyses will take place 
in two domains: (1) exploring the aberrant innate and adaptive 
immune mechanisms and (2) validating immune pathways or 
biomarkers identified by microbiomic or metabolomic profiling.
Immunohistochemistry will be performed using paraffin 
blocks cut into 4 µm sections for staining using a Discovery XT 
auto-stainer (Ventana Medical Systems, Inc., Tucson, AZ, USA). 
Slide images will be acquired using the Vectra 3.0 Automated 
Quantitative Pathology Imaging System (Perkin Elmer, Waltham, 
MA, USA), using techniques optimized by our group at Newcastle. 
Antigens of interest will be quantified digitally. Leukocyte infil-
trates associated with NEC will be identified using antibodies 
to several epitopes, for example, markers of inflammatory cell 
subsets, cellular proliferation, cytotoxic granule expression, 
transcription factors, or cytokines. Many of these antibodies 
have been previously optimized for intestinal tissue by the team 
at Newcastle, and new antibodies will be optimized as required 
informed by data generated in other work strands of this project. 
Staining of “healthy” resection margins from the same patient will 
be undertaken where possible and control analyses will be per-
formed by use of matched non-NEC control tissue collected from 
MAGPIE infants, supplemented if needed by further samples from 
the Newcastle upon Tyne Hospitals biorepository (e.g., cases of 
spontaneous neonatal perforation). Targeted exploratory histology 
will validate immune mechanisms highlighted by metabolomics or 
microbial assays, and in situ hybridization may also be performed 
to identify transcription of relevant immune pathways identified 
by VOC, microbiomic, or metabolomic profiling.
sample size estimates
Sample size requirements for each element of this study have been 
evaluated and are based on both published data and practical/
logistical aspects from our existing work and that from other 
published studies. These considerations include
 1. The duration, estimated start time, and recruitment rate for 
ELFIN, along with the estimated start date for MAGPIE and 
logistical issues in establishing recruitment from 10 hospital 
sites.
 2. The trial efficacy and disease event rate will not be known until 
the main trial completes. The incidence of NEC (Bell stage 2 
or greater) is expected to be 5–10% and for LOS <20%, and 
some infants will have both diseases. Recruiting 480 infants 
will identify between 70 and 100 “disease” cases, 10–20 
cases requiring gut surgery, and provide well sampled “non-
diseased” infants with varying clinical risk factors, exposures, 
and outcomes.
 3. VOC analysis may identify several individual compounds; in 
our recent paper publishing the methodology, we show that on 
average 31.3 ± 10.5 (mean and SD) VOCs were identified per 
sample (82). At a power of 80%, and two-sided significance at 
the 5% level, we would need 50 infants per trial intervention 
group to show an increase in 5 VOCs. The SD for each sample 
was 2.9 ±  1.3 compounds and on average 90% of the VOC 
abundances showed a coefficient of variation smaller than 
30%. Our data also showed in a study of 13 infants, which 
VOC number in healthy neonates significantly increased with 
age (0.49 extra VOCs per day 95% CI 0.12–0.86), a trend not 
seen in those who developed NEC (64).
 4. Microbiomic data complexities means that the sample size 
necessary to evaluate the actions of different interventions and 
the incidence of disease is dependent on effect size, the num-
ber of interacting factors, and their correlation. For a power of 
80% to detect a 50% difference in community profile patterns 
arising from a categorical descriptor of microbial community 
variation, using a two-sided test at a significance level of 5%, 
the study needs ~200 samples. In our previous studies (1) 12 
twin pairs analyzed (gut microbial profiling) using PLS-DA 
showed highly significant correlations between pairs (53) and 
(2) examination of 136 samples from 32 patients (n = 20 NEC 
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or LOS) showed significant differences (p = 0.002) in microbi-
omic patterns between diseased and healthy individuals (24).
 5. Using immunohistochemical data from our group (83), and 
assuming that any differences between disease and control 
will be greater than those in healthy individuals, and using a 
two-sample t-test, our proposed sample size of 20 would give 
80% power to detect a difference of 0.66 (66%) in cells/crypt 
cross section at a significance level of 5% and an approximated 
SD of 0.5 (50%).
 6. Mixed-effects models, which we propose for modeling the 
direct effects of the microbiome on disease risk, are economi-
cal with power because the residual variance of these models 
is smaller since some of it is accounted for in the random 
effect. Using the method by Cohen (84), we calculate that a 
GLM would have a power of 82% with 10 predictors and 50 
for a “large” effect size (f2 = 0.35, R2 = 0.51) at the 5% level 
of significance, and a power of 47% for a “medium” effect 
size (f2 = 0.15, R2 = 0.36) at the 5% level of significance. With 
n = 100 the calculated powers are 99% for a large effect size 
and 74% for a medium effect size. Including random effects 
in the GLM would increase power at the same effect size or 
conversely permit smaller effect sizes at the same power. The 
power analysis of an SEM is altogether more complex because 
it relies on the goodness-of-fit criteria selected for the model. 
Power at the model level may be low when there are few model 
degrees of freedom even for a reasonably large sample size; 
requiring greater than 100 samples if there are fewer than 20 
model degrees of freedom (85). We will supplement these 
models where needed using a Bayesian SEM approach.
statistical analysis
There are three major modeling issues that have to be addressed 
in this analytical pathway:
 (i) the multivariate nature of the microbiome and metabolome, 
and data generated from immunohistochemistry;
 (ii) the longitudinal/developmental component in the neonate, 
which will lead to repeated measures of disease state and 
microbiome on the same individuals, and
 (iii) the interdependence and interactions between different 
predictors, which may have both direct and indirect effects 
on incidence and progression of disease.
The analytical approach used in this study will focus on 
modeling the relationship between putative risk factors, trial 
interventions, and incidence of NEC and LOS from longitudinal 
data capturing variation in both risk factors and disease through 
time, and the any differences in non-diseased cases between 
trial arms. We will use a progressive modeling strategy based 
on combining multivariate analyses of micro- and metabolomic 
immunological data, with mixed-effect modeling of outcome 
in relation to drivers of disease; and finally, mixed-effect SEM 
to quantify the importance of interacting factors and drivers. 
Specifically, we will
 (i) quantify the impacts of individual risk factors in causing 
disease;
 (ii) quantify the effects of direct and indirect risk factors on 
disease;
 (iii) quantify the dynamics of pathogens, the neonatal microbi-
ome, the immune response, and their impact on outcomes, 
and
 (iv) identify the impacts of trial interventions and clinical man-
agement on the drivers and disease.
anTiciPaTeD resUlTs FrOM analYsis 
OF MicrOBiOMe anD MeTaBOlOMe
We will use multivariate ordination techniques to summarize and 
visualize the major trends in variation in microbial community 
composition of infants’ stool collected. The analyses will identify 
those taxa most closely associated with microbiome change 
through time. We will use canonical ordination to quantify the 
impacts of other covariates (diet, age, and interventions) on the 
microbiome composition. We will identify key microbial taxa in 
the ordination space that capture the trend in variation in relation 
to disease and use these with the results of the ordination as input 
variables for the subsequent mixed-effect and SEM analyses below. 
To ensure the results are not spurious, the observed differences 
in metabolomic profiles will be validated by permutation testing 
in MetaboAnalyst 3.0 (86). Where appropriate, significance of 
categorical variables were determined using the non-parametric 
Mann–Whitney test for two category comparisons or the 
Kruskal–Wallis test when comparing three or more categories 
(87) and all p-values were adjusted for multiple comparisons with 
the false discovery rate algorithm (88).
MixOmics (89) will be implemented to determine the correla-
tion between the relative abundance of the dominant bacterial 
taxa from 16S rRNA gene sequencing and the intensity of metab-
olites of interest by sparse partial least squares regression (90). 
Longitudinal and network analyses will facilitate investigations 
into the directionality of any observations. Tax4Fun (62) will be 
used to infer the metabolic potential of the microbiome based on 
the 16S data. Model-based integration of metabolite observations 
and species abundances will then be applied to determine biologi-
cally feasible correlations between the inferred bacterial KEGG 
orthology and the resulting metabolites of interest (91). This will 
determine which metabolites are likely to be bacterial derived. It 
is important to note that in the course of data generation, new 
tools are likely to emerge that can perform distinct analyses on 
multi-omic data. Where appropriate we will incorporate such 
tools where they are likely to (1) outperform existing tools and/
or (2) allow novel analyses to be performed.
Quantifying the Direct and indirect impact 
of risk Factors on Disease
We will use repeated measure mixed-effect modeling to quantify 
the direct effects of microbiome on risk of disease while adjusting 
for clinical factors. We will use case as the random effect and adjust 
for autocorrelation in the response using appropriate correlation 
structures in the model. The applicants have used this approach 
extensively to investigate the epidemiology of food-borne patho-
gens (92). We will use an SEM approach to quantify direct and 
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indirect effects of risk factors on the incidence of disease. We will 
develop a set of models that characterize the relationship between 
clinical factors, the changes in gut microbial community types, 
developmental stage (postnatal and postmenstrual age), and 
comorbidities associated with disease onset and then challenge 
the model with the data derived from the laboratory and clinical 
data collection (93).
Plan for interim statistical analyses
The MAGPIE study funder (NIHR) and the project team agreed 
that it would be appropriate to conduct a futility-type analysis 
to ensure there are measurable impacts on the microbiome 
after ~150 (of the total planned 480) infants have been recruited, 
and prior to commencing further analysis of the microbiome and 
metabolome. The ELFIN study is blinded so any laboratory and 
statistical analysis of anonymized samples while recruitment 
continues will be conducted by investigators blinded to trial 
interventions. Blinding to trial intervention arm will also be 
maintained while gut tissue is examined.
For the interim analyses we will
 1. Select samples taken before disease onset at around 7–10 days 
after commencing the trial IMP (lactoferrin or placebo) in up 
to 60 infants per trial group so as to compare and assess micro-
bial community changes between trial groups. Because other 
risk factors are also associated with disease (e.g., gestation, 
postnatal age, etc.), we will use progressive model building 
that investigates microbial community dynamics in relation 
to these covariates.
 2. Use multivariate ordination and classification approaches to 
quantify trial intervention group differences in gut microbial 
communities. This will (i) quantify the variation in microbial 
community composition before disease onset and (ii) develop 
suitable covariates describing microbial community variation 
for inclusion in statistical analysis as risk factors for disease.
 3. Use unconstrained ordination to investigate trends in commu-
nity composition and to identify those microbial taxa from the 
NGS data that contribute most to community variation. These 
axes may be used as covariates in the subsequent analysis.
 4. Use constrained ordination to investigate the impact of trial 
intervention group on community variation prior to disease 
onset.
 5. Use divisive classification approaches to identify classes of 
microbial community among the cases. This will create a suite 
of categorical descriptors of community composition. Higher 
level community descriptors (diversity, evenness, rate of 
change in ordination score) will be derived in case the overall 
structure of the community is an important driver.
 6. In the interim analyses, we will determine whether there is 
any effect on the total microbial community differences or 
on individual bacterial taxa using MANOVA and consider 
a difference in the microbial community of p <  0.05 to be 
proof an effect. If the p value is between 0.05 and 0.1, we will 
consider this to be strong evidence of a likely effect, where 
statistical significance might subsequently be achieved in 
an analysis with larger numbers and/or greater numbers of 
diseased or high risk cases and will complete the study as 
planned. Regression models and SEM will adjust for potential 
confounding variables such as age, sex, gestation, and feed and 
antibiotic exposures.
sUMMarY
The MAGPIE study provides a unique opportunity to explore 
the interaction between nutritional and feeding interventions 
on gut microbiota in early life in preterm infants, and within the 
context of large randomized trials. Next-generation sequenc-
ing and metabolomic techniques produce large datasets that 
require complex modeling in order to present findings of clinical 
relevance. While these new “omic” techniques have provided 
unique insights into complex multifactorial diseases such as 
NEC, current studies are limited by their observational nature 
and are at significant risk from type I errors due to residual con-
founding and/or reverse causation. Prospective trials are needed 
to determine direct causation due to clinical interventions such 
as milk feed rate or enteral lactoferrin supplementation. Nesting 
mechanistic evaluation within these trials using non-invasive and 
safe sampling increases the value of large RCTs. This may produce 
important new data of diagnostic and therapeutic relevance or 
identify differences in responses between groups of infants 
(i.e., exploring in what setting interventions may be most or 
least efficacious), as well as potentially providing information 
about risk stratification for future studies. NEC and LOS remain 
extremely prevalent and serious diseases in preterm infants and 
both are associated with considerable mortality and morbid-
ity, as well as generating significant health-care resource costs. 
Studies such as MAGPIE will improve our understanding of the 
basic biology of health and disease and the role of early life gut 
microbiota colonization in a high risk group of patients where 
mechanistic understanding is limited.
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